Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chattem’s ACT goes global

This article was originally published in The Tan Sheet

Executive Summary

The Chattanooga, Tenn.-based firm announces an agreement May 7 to acquire the Western Europe rights to ACTas well as worldwide trademark rights from Johnson & Johnson for $4.1 mil. plus certain assumed liabilities. The European Commission approved the transaction and the deal is expected to close in late May. J&J is divesting ACT as a condition of the EC's approval of J&J's Pfizer Consumer Healthcare acquisition and "certain regulatory requirements in connection with the acquisition in Greece," the firm says. Chattem acquired ACT and five other OTC brands from J&J/Pfizer in January 2007 (1"The Tan Sheet" Feb. 19, 2007, p. 10)...

You may also be interested in...

Global ACT deal closes

Chattem announces May 29 the closing of an agreement to acquire the rights to anti-cavity mouthwash ACT in Western Europe together with worldwide trademark rights for $4.1 mil. and assumed liabilities. The Chattanooga, Tenn.-based firm announced the agreement May 7 after the European Commission approved it (1"The Tan Sheet" May 14, 2007, In Brief). Chattem acquired ACT and other brands in January 2007 as Johnson & Johnson divested brands in connection with its Pfizer Consumer Healthcare purchase (2"The Tan Sheet" Feb. 19, 2007, p. 10)...

Chattem Hopes Brands Acquired From J&J Offset Cool Sales Of Pro-Therapy

For 2007, Chattem expects sales of products recently acquired from Johnson & Johnson to rival its existing "big three," of Gold Bond skin care, Icy Hot topical analgesics and Selsun medicated shampoos

First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations

With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts